Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

Cancers - Switzerland
doi 10.3390/cancers11070984
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Targeting Angiogenesis in Cancer Treatments: Where Do We Stand?

Journal of Pharmacy and Pharmaceutical Sciences
MedicinePharmacologyPharmaceutical Science
2016English

Blockchain in Academia: Where Do We Stand and Where Do We Go?

2020English

C-Reactive Protein in Bladder Cancer: Where Do We Stand?

Nature Reviews Urology
Urology
2013English

Systemic Chemotherapy in Gastric Cancer: Where Do We Stand Today?

Oncologist
Cancer ResearchMedicineOncology
1998English

High Energy Neutrino Astronomy: Where Do We Stand, Where Do We Go?

Physics of Particles and Nuclei
High Energy PhysicsNuclear
2018English

Schistosomiasis Vaccines: Where Do We Stand?

Parasites and Vectors
ParasitologyInfectious Diseases
2016English

Evaluating Response to Immunotherapy With 18f-FDG PET/CT: Where Do We Stand?

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2020English

Where Do We Stand After Coty?

Competition Law Journal
2018English

Quantum Computers: Where Do We Stand?

Europhysics News
AstronomyPhysics
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy